Skip to main contentAI and Advanced
/
LUPIN · NSEBSE SENSEX77,590+0.07%BSE |
NIFTY 5024,253.15+0.09%NSE |
NIFTY BANK57,542.2+0.08%NSE |
NIFTY IT30,546.35-0.41%NSE |
NIFTY AUTO29,336.7+0.12%NSE |
NIFTY FMCG47,756.15-0.22%NSE |
NIFTY PHARMA26,513.5+0.37%NSE |
NIFTY 50023,536.4+0.10%NSE |
LU
NSE · Equity shares · Biotechnology & Drugs-23.50 · -1.06%
Lupin LUPIN
NSE:INR 2,201.5
BSE:INR 2,395
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for LUPIN
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,225
Day rangeINR 2,201.5 — INR 2,237.7
52-week rangeINR 1,875 — INR 2,529.5
Volume5.32 L
Market cap1.10 L
P/E18.66
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)27,958.03
Net Income (INR Cr)5,332.84
Rev Growth (5 Year %)13.02
EPS Growth (5 Year %)34.23
P/E Ratio18.66
Book Value362.71
EPS127.78
Price/BV6.07Computed
Research path: Interpret Lupin's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
LUPINLupin1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 38,364.83 | 29,204.88 | 23,997.18 |
| Accumulated Depreciation Total | -5,534.62 | -4,956.84 | -4,580.63 |
| Cash Equivalents | 4,167.73 | 421.59 | 272.15 |
| Other Liabilities Total | 843.19 | 692.23 | 721.08 |
| Accrued Expenses | 759.05 | 512.38 | 419.25 |
| Long Term Debt | 1,643.39 | 1,766.23 | 0 |
| Common Stock Total | 91.44 | 91.32 | 91.14 |
| Other Equity Total | 202.3 | -239.61 | -163.59 |
| Other Current Assets Total | 1,386.64 | 1,235.42 | 37.24 |
| Prepaid Expenses | 114.62 | 104.29 | 99.89 |
| Total Assets | 38,364.83 | 29,204.88 | 23,997.18 |
| Current Portof LT Debt/Capital Leases | 529.14 | 401.71 | 96.58 |
| Additional Paid-In Capital | 1,359.56 | 1,287.59 | 1,179.44 |
| Total Equity | 22,448.27 | 17,203.5 | 14,290.29 |
| Long Term Investments | 92.54 | 97.9 | 227.7 |
| Retained Earnings(Accumulated Deficit) | 20,730.77 | 15,980.22 | 13,068.93 |
| Total Common Shares Outstanding | 45.72 | 45.66 | 45.57 |
| Property/Plant/Equipment Total-Gross | 11,678.88 | 10,460.47 | 10,074.85 |
| Tangible Book Valueper Share Common Eq | 362.71 | 273.15 | 222.39 |
| Goodwill Net | 2,658.53 | 2,232.61 | 2,325.04 |
| Total Liabilities | 15,916.56 | 12,001.38 | 9,706.89 |
| Total Debt | 6,616.18 | 5,447.77 | 2,921.77 |
| Short Term Investments | 3,780.25 | 1,476.38 | 1,195.26 |
| Cashand Short Term Investments | 7,947.98 | 3,020.07 | 2,178.54 |
| Total Receivables Net | 8,112.8 | 6,721.78 | 5,932.06 |
| Notes Payable/Short Term Debt | 3,948.78 | 3,015.56 | 2,669.91 |
| Deferred Income Tax | 218.77 | 226.41 | 245.87 |
| Accounts Receivable-Trade Net | 6,604.06 | 5,497.1 | 4,692.05 |
| Property/Plant/Equipment Total-Net | 6,144.26 | 5,503.63 | 5,494.22 |
| Minority Interest | 65.1 | 90.85 | 83.16 |
| Total Current Liabilities | 12,651.24 | 8,961.39 | 8,501.5 |
| Total Inventory | 6,465.34 | 5,717.02 | 5,199.92 |
| ESOP Debt Guarantee | 64.2 | 83.98 | 114.37 |
| Accounts Payable | 4,173.13 | 2,958.16 | 2,958.11 |
| Other Currentliabilities Total | 3,241.14 | 2,073.58 | 2,357.65 |
| Total Long Term Debt | 2,138.26 | 2,030.5 | 155.28 |
| Intangibles Net | 3,207.2 | 2,499.75 | 1,831.57 |
| Other Long Term Assets Total | 2,020.71 | 1,847.28 | 399.21 |
| Note Receivable-Long Term | 214.21 | 225.13 | 271.79 |
| Total Current Assets | 24,027.38 | 16,798.58 | 13,447.65 |
| Capital Lease Obligations | 494.87 | 264.27 | 155.28 |
| Cash | Not available | 1,122.1 | 711.13 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.15
Price to Sale Ratio3.92
Growth
Debt 5Yr CAGR %5.22
Margins
Operating Margin 12m22.27
Operating Margin 5y Avg12.28
Net Profit Margin 12m19.16
Net Profit Margin 5y9.19
Yield
Dividend Yield %0.75
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk21.61
Analyst consensus
ConsensusHold
Consensus score2.67
Analyst opinions36
Strong Sell count3
Sell count4
Hold count13
Buy count10
Strong Buy count6
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 46.85%
- FII
- 22.42%
- MF
- 14.84%
- Other
- 15.89%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Pharma stocks close lower; Lupin down over 4% after Trump announces steep tariffs on generics - ET ManufacturingMarket news · 22 Jul 2026, 4:43 pm
Pharma stocks close lower; Lupin down over 4% after Trump announces steep tariffs on generics ET Manufacturing
Lupin Transfers Cancer Drug Assets to Kaveri Therapeutics - Pharmacy BusinessMarket news · 22 Jul 2026, 2:33 pm
Lupin Transfers Cancer Drug Assets to Kaveri Therapeutics Pharmacy Business
US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline - BusinessLineMarket news · 22 Jul 2026, 2:08 pm
US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline BusinessLine
Lupin, Aurobindo, Sun Pharma fall up to 4%: Why are pharma stocks falling today? - India TodayMarket news · 22 Jul 2026, 10:18 am
Lupin, Aurobindo, Sun Pharma fall up to 4%: Why are pharma stocks falling today? India Today
Gland Pharma, Lupin, Dr Reddy's: All Nifty Pharma Stocks In Red After Trump's Drug Tariff Plan - NDTV ProfitMarket news · 22 Jul 2026, 9:49 am
Gland Pharma, Lupin, Dr Reddy's: All Nifty Pharma Stocks In Red After Trump's Drug Tariff Plan NDTV Profit
Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sen - News18Market news · 22 Jul 2026, 9:39 am
Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sen News18
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.18.0000 per share(900%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsTo consider other business matters.
- annual General MeetingPOM
ShareKeyX Community
Discussion and sentiment for Lupin
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Lupin Limited is a pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. It has presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, GastroIntestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its ophthalmology portfolio includes over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals across European markets. Its diabetes brands include GIBTULIO, AJADUO, GIBTULIO MET, ONDERO, ONDERO MET, and Huminsulin.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- LUPIN
- BSE Code
- 500257
Questions
Stock FAQ
What is the symbol and ISIN of Lupin?
Lupin has the symbol LUPIN and ISIN - INE326A01037.
What is the current price of Lupin?
Lupin is currently trading at INR 2,201.50.
What are the year high and year low of Lupin?
Lupin has a year high of INR 2,529.50 and a year low of INR 1,875.00.
What is the market capitalization of Lupin?
Lupin has a market capitalization of INR 1.10 lakh crore.
What is the P/E ratio of Lupin?
Lupin has a P/E ratio of 18.66.
What is the dividend yield of Lupin?
Lupin has a dividend yield of 0.75%.
How is the financial performance of Lupin based on revenue, net income, and EPS?
Lupin has revenue of INR 27,958.03 crore, net income of INR 5,332.84 crore, and EPS of INR 135.10.
What is the book value of Lupin?
Lupin has a book value of INR 362.71.
What is the debt-to-equity ratio of Lupin?
Lupin has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Lupin?
Lupin has a price-to-book ratio of 6.07 and a price-to-sales ratio of 3.92.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.